All literature
2007Annals of the New York Academy of SciencesReview

Thymosin alpha1: a historical overview

Garaci E.

Longevity

Editor's note

Garaci's history of how thymosin alpha-1 got from Goldstein's thymus extracts to an actual marketed drug in 35-plus countries. Mostly relevant for sepsis and chronic-viral-infection use cases. Editorial-adjacent — pair with primary trial data.

Read the paperDOI  10.1196/annals.1415.039

Related literature

Adjacent reading.

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.

Thymosin alpha1: a historical overview · SavePeptides